Carlsmed Reports First Quarter 2026 Financial Results
Globe Newswire (Tue, 5-May 4:01 PM ET)
Carlsmed, Inc. To Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 28-Apr 4:01 PM ET)
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
Globe Newswire (Tue, 14-Apr 8:00 AM ET)
Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
Globe Newswire (Wed, 1-Apr 4:01 PM ET)
Market Chameleon (Thu, 4-Dec 5:53 AM ET)
Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.
Carlsmed trades on the NASDAQ stock market under the symbol CARL.
As of June 22, 2026, CARL stock price climbed to $10.30 with 2,284 million shares trading.
CARL has a beta of 2.40, meaning it tends to be more sensitive to market movements. CARL has a correlation of 0.18 to the broad based SPY ETF.
CARL has a market cap of $280.00 million. This is considered a Small Cap stock.
Last quarter Carlsmed reported $16 million in Revenue and -$.32 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.08.
The top ETF exchange traded funds that CARL belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.
CARL support price is $9.58 and resistance is $10.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CARL shares will trade within this expected range on the day.